Today: 9 June 2026
AppLovin stock jumps nearly 5% as traders chase another swing in APP shares
26 February 2026
1 min read

AppLovin stock jumps nearly 5% as traders chase another swing in APP shares

New York, Feb 26, 2026, 15:20 EST — Regular session

  • AppLovin climbed roughly 5% during afternoon hours, adding to a rebound that’s stretched over the past two sessions.
  • This week, an insider filing showed routine tax withholding linked to the vesting of RSUs.
  • Regulatory worries linger for investors, who are also parsing ad-tech earnings for any signals about demand heading into 2026.

AppLovin Corp climbed 4.8% to $441.80 late Thursday, having bounced between $417.56 and $445.90 during the session. The Nasdaq stock had just logged a 7.2% gain the day before.

AppLovin’s stock has become something of a barometer for digital ad momentum and investors’ taste for high-growth software, even as the broader market sagged on Thursday. That’s why the move stands out.

This comes as ad-tech investors hunt for signals in sector earnings and outlooks. Shares of The Trade Desk dropped on a softer-than-expected first-quarter revenue forecast, stoking fresh anxiety over a potential slowdown in ad demand.

No new word from AppLovin on Thursday. A recent Form 4 revealed CFO Matthew Stumpf had shares withheld for taxes related to vested RSUs—stock grants that vest over time.

Shares have swung as traders digest potential fallout tied to the company’s ad-targeting methods. The U.S. Securities and Exchange Commission is still investigating AppLovin, according to Bloomberg News last week, with Reuters also citing the ongoing probe.

Earlier this month, AppLovin posted December-quarter results that beat sales forecasts, and its outlook for first-quarter revenue came in ahead of Wall Street’s targets. Even so, the company flagged intensifying competition. Jefferies analysts, anticipating the update, warned in a note that stepped-up bidding from Meta on Apple’s iOS traffic poses a “genuine challenge” for both pricing and margins. https://www.reuters.com/business/applovin-…

The risk? Pretty clear. If the investigation drags on—or if platform partners tighten the rules—performance could feel the squeeze. Mobile app marketing demand would take a hit if ad spending cools. And investors haven’t hesitated to react sharply to guidance that strikes them as weak.

Now, attention turns to regulatory news and hints from digital-ad earnings on the horizon. AppLovin, for its part, has said it’ll file its definitive proxy statement for the 2026 annual meeting within 120 days after the fiscal year ends.

Stock Market Today

  • Wheat Prices Mixed as Winter Wheat Gains on U.S. Crop Progress
    June 9, 2026, 9:22 AM EDT. Wheat markets closed mixed on Monday, with winter wheat futures rising across Chicago and Kansas City exchanges, while Minneapolis spring wheat fell slightly. The U.S. Department of Agriculture's Crop Progress report showed 92% of winter wheat heading, 7% ahead of average, and spring wheat planting at 98%, with improving crop conditions. Export inspections dropped 20.65% from last week but marketing year shipments rose 9.13% compared to last year. Ukraine's wheat crop estimate increased by 1.8 million tonnes to 21.7 million tonnes. Futures finished with Chicago SRW wheat up 1 to 3 ¼ cents and Kansas City HRW wheat up 2 ¼ to 9 cents, contrasting the modest decline in Minneapolis spring wheat.

Latest articles

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
AmpliTech’s 5G Radio Test Moves AMPG Shares

AmpliTech’s 5G Radio Test Moves AMPG Shares

9 June 2026
AMPG soared 26.7% to $6.57 after AmpliTech revealed its 64T64R Massive MIMO radio was the only one of its kind at O-RAN PlugFest, showing interoperability with major carriers’ equipment, but no new orders were announced, leaving sales conversion as the key investor focus.
Cartesian Growth Ticker Change Draws Trader Attention to Factorial Energy

Cartesian Growth Ticker Change Draws Trader Attention to Factorial Energy

9 June 2026
Factorial Energy surged 16% to $13.80 in its Nasdaq debut as FAC, with premarket trading near $20.70, after replacing CGCT via SPAC merger that raised over $100 million for battery commercialization and implied a $1.3 billion equity value; former CGCT shares now trade as FAC, with founders retaining majority voting power and staged lock-up releases ahead.
Pfizer Falls in Premarket; Fresh FDA Approval Not Lifting the Stock

Pfizer Falls in Premarket; Fresh FDA Approval Not Lifting the Stock

9 June 2026
Pfizer shares fell 1.7% premarket to $25.62 as investors weighed an FDA label expansion for hemophilia drug Hympavzi—now the first subcutaneous non-factor therapy for children 6-11 with hemophilia B—against slower progress in obesity drugs, with mid-stage data for weight-loss shot berobenatide showing a 23.3% vomiting rate and no immediate growth catalyst for the $147 billion company.
Intel stock slides as chip rally cools — what’s driving INTC today
Previous Story

Intel stock slides as chip rally cools — what’s driving INTC today

GSK share price today: stock edges up after Japan and China reviews, plus $950 million 35Pharma deal
Next Story

GSK share price today: stock edges up after Japan and China reviews, plus $950 million 35Pharma deal

Go toTop